Anchoring β-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells

He, Jianhua; Zhou, Xingyao; Xu, Fengfei; He, Hongliang; Ma, Shuangyan; Zhang, Mengyuan; Zhang, Wenli; Liu, Jianping

doi:10.1016/j.ejpb.2022.04.005

Cited by 5 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism study indicated that β-CD-ST-d-rHDL inhibited the secretion of the inflammatory factor TNF-α through the mevalonate pathway and alleviating the inflammatory response. 200 The findings show that d-rHDL can be used as a drug carrier and active agent acting collaboratively with other anti-AS drugs. Furthermore, they cross-linked the aforementioned β-CD-anchored rHDL, NP 3 ST , with HA-ferrocene (HA-Fc) conjugates through multivalent host-guest interactions and prepared the nanoassemblies HA-Fc/NP 3 ST .…”

Section: Atherosclerosis (As)mentioning

confidence: 91%

“… 195 – 197 Recently, He et al designed a β-cyclodextrins (β-CD)-anchored rHDL, in which β-CD was utilized to efflux intracellular cholesterol. 198 – 200 First, the interaction between β-CD and drug-loaded discoidal-rHDL (d-rHDL) was investigated using the shuttle/sink model. 198 They uncovered that β-CD could enhance macrophage-cholesterol outflow and move it to d-rHDL.…”

Section: Atherosclerosis (As)mentioning

confidence: 99%

See 1 more Smart Citation

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Combining existing drug therapy is essential in developing new therapeutic agents in disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established in treating extensive human diseases. Attributed to synergistic effects by targeting various disease pathways and advantages, such as reduced administration dose, decreased toxicity, and alleviated drug resistance, combinatorial treatment is now being pursued by delivering therapeutic agents to combat major clinical illnesses, such as cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders and neurodegenerative diseases. Combinatorial therapy involves combining or co-delivering two or more drugs for treating a specific disease. Nanoparticle (NP)-mediated drug delivery systems, i.e., liposomal NPs, polymeric NPs and nanocrystals, are of great interest in combinatorial therapy for a wide range of disorders due to targeted drug delivery, extended drug release, and higher drug stability to avoid rapid clearance at infected areas. This review summarizes various targets of diseases, preclinical or clinically approved drug combinations and the development of multifunctional NPs for combining therapy and emphasizes combinatorial therapeutic strategies based on drug delivery for treating severe clinical diseases. Ultimately, we discuss the challenging of developing NP-codelivery and translation and provide potential approaches to address the limitations. This review offers a comprehensive overview for recent cutting-edge and challenging in developing NP-mediated combination therapy for human diseases.

show abstract

Section: Atherosclerosis (As)mentioning

confidence: 91%